Although CAP’s anti-obesity and lipid-lowering effects via TRPV1 activation have been demonstrated [17], its therapeutic potential against MASLD and associated insulin resistance remains poorly defined. Here, TRPV1 is linked to obesity due to melanocortin 4 receptor deficiency.